The settlement required First DataBank (FDB) to reduce the AWP mark-up from 1.25 to 1.20 times the Wholesale Acquisition Cost (WAC) for 1,442 NDCs identified in the litigation. FDB set the mark-up at 1.20 for all drugs independent of the litigation on September 26, 2009. The roll back of the WAC-to-AWP spread led to a 4% reduction in their AWP. FDB also stopped publishing AWP data on September 26, 2011, two years after the rollback adjustments were implemented. First DataBank continues to publish non-AWP drug pricing information, including WAC, Direct Price, and suggested wholesale price.